IBDEI057 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2180,2)
 ;;=^295163
 ;;^UTILITY(U,$J,358.3,2181,0)
 ;;=V01.79^^21^205^9
 ;;^UTILITY(U,$J,358.3,2181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2181,1,4,0)
 ;;=4^V01.79
 ;;^UTILITY(U,$J,358.3,2181,1,5,0)
 ;;=5^VIRAL DIS CONTACT NEC
 ;;^UTILITY(U,$J,358.3,2181,2)
 ;;=^331577
 ;;^UTILITY(U,$J,358.3,2182,0)
 ;;=V01.81^^21^205^2
 ;;^UTILITY(U,$J,358.3,2182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2182,1,4,0)
 ;;=4^V01.81
 ;;^UTILITY(U,$J,358.3,2182,1,5,0)
 ;;=5^CONTACT/EXPOSURE TO ANTHRAX
 ;;^UTILITY(U,$J,358.3,2182,2)
 ;;=^328701
 ;;^UTILITY(U,$J,358.3,2183,0)
 ;;=V01.82^^21^205^3
 ;;^UTILITY(U,$J,358.3,2183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2183,1,4,0)
 ;;=4^V01.82
 ;;^UTILITY(U,$J,358.3,2183,1,5,0)
 ;;=5^EXPOSURE TO SARS
 ;;^UTILITY(U,$J,358.3,2183,2)
 ;;=^329963
 ;;^UTILITY(U,$J,358.3,2184,0)
 ;;=V01.89^^21^205^1
 ;;^UTILITY(U,$J,358.3,2184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2184,1,4,0)
 ;;=4^V01.89
 ;;^UTILITY(U,$J,358.3,2184,1,5,0)
 ;;=5^CONT/EXP TO OTHER COMM DISEASE
 ;;^UTILITY(U,$J,358.3,2184,2)
 ;;=^328661
 ;;^UTILITY(U,$J,358.3,2185,0)
 ;;=V02.60^^21^206^6
 ;;^UTILITY(U,$J,358.3,2185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2185,1,4,0)
 ;;=4^V02.60
 ;;^UTILITY(U,$J,358.3,2185,1,5,0)
 ;;=5^VIRAL HEPATITIS CARRIER, UNSPE
 ;;^UTILITY(U,$J,358.3,2185,2)
 ;;=^295173
 ;;^UTILITY(U,$J,358.3,2186,0)
 ;;=V02.61^^21^206^3
 ;;^UTILITY(U,$J,358.3,2186,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2186,1,4,0)
 ;;=4^V02.61
 ;;^UTILITY(U,$J,358.3,2186,1,5,0)
 ;;=5^HEPATITIS B CARRIER
 ;;^UTILITY(U,$J,358.3,2186,2)
 ;;=^317946
 ;;^UTILITY(U,$J,358.3,2187,0)
 ;;=V02.62^^21^206^4
 ;;^UTILITY(U,$J,358.3,2187,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2187,1,4,0)
 ;;=4^V02.62
 ;;^UTILITY(U,$J,358.3,2187,1,5,0)
 ;;=5^HEPATITIS C CARRIER
 ;;^UTILITY(U,$J,358.3,2187,2)
 ;;=^317947
 ;;^UTILITY(U,$J,358.3,2188,0)
 ;;=V02.69^^21^206^5
 ;;^UTILITY(U,$J,358.3,2188,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2188,1,4,0)
 ;;=4^V02.69
 ;;^UTILITY(U,$J,358.3,2188,1,5,0)
 ;;=5^OTHER VIRAL HEPATITIS CARRIER
 ;;^UTILITY(U,$J,358.3,2188,2)
 ;;=^317948
 ;;^UTILITY(U,$J,358.3,2189,0)
 ;;=V02.7^^21^206^2
 ;;^UTILITY(U,$J,358.3,2189,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2189,1,4,0)
 ;;=4^V02.7
 ;;^UTILITY(U,$J,358.3,2189,1,5,0)
 ;;=5^GONORRHEA CARRIER
 ;;^UTILITY(U,$J,358.3,2189,2)
 ;;=^295174
 ;;^UTILITY(U,$J,358.3,2190,0)
 ;;=V02.9^^21^206^1
 ;;^UTILITY(U,$J,358.3,2190,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2190,1,4,0)
 ;;=4^V02.9
 ;;^UTILITY(U,$J,358.3,2190,1,5,0)
 ;;=5^CARRIER-INFECTIOUS ORGANISM NEC
 ;;^UTILITY(U,$J,358.3,2190,2)
 ;;=^295176
 ;;^UTILITY(U,$J,358.3,2191,0)
 ;;=V08.^^21^207^1
 ;;^UTILITY(U,$J,358.3,2191,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2191,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,2191,1,5,0)
 ;;=5^ASYMPT HIV STATUS
 ;;^UTILITY(U,$J,358.3,2191,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,2192,0)
 ;;=V49.0^^21^208^9
 ;;^UTILITY(U,$J,358.3,2192,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2192,1,4,0)
 ;;=4^V49.0
 ;;^UTILITY(U,$J,358.3,2192,1,5,0)
 ;;=5^DEFICIENCIES OF LIMBS
 ;;^UTILITY(U,$J,358.3,2192,2)
 ;;=^295484
 ;;^UTILITY(U,$J,358.3,2193,0)
 ;;=V49.1^^21^208^16
 ;;^UTILITY(U,$J,358.3,2193,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2193,1,4,0)
 ;;=4^V49.1
 ;;^UTILITY(U,$J,358.3,2193,1,5,0)
 ;;=5^MECHANICAL PROB W LIMBS
 ;;^UTILITY(U,$J,358.3,2193,2)
 ;;=^295485
 ;;^UTILITY(U,$J,358.3,2194,0)
 ;;=V49.2^^21^208^17
 ;;^UTILITY(U,$J,358.3,2194,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2194,1,4,0)
 ;;=4^V49.2
 ;;^UTILITY(U,$J,358.3,2194,1,5,0)
 ;;=5^MOTOR PROBLEMS W LIMBS
